IL1B and breast cancer: It has also been shown that NLRP3 decreases antitumor immunity in T cells and NK cells, which creates an inflammatory environment supporting BC progression and metastasis by activating inflammatory signaling pathways, such as the NF-κB/STAT 1/3 and IL-1β/IL-1RI/β-catenin pathways [36, 41].